Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifenprodil in Multiple Sclerosis
NCT06330077Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Ifenprodil with Placebo (2 arms). Primary endpoint: Change in P100 latency according to visual evoked potential at 12 months. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
ifenprodil
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06330077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06330077.